Oncology for the Inquisitive Mind

"We go to the moon and other places not because they are easy, but because they are hard." So spoke US President John F. Kennedy, in a speech that galvanised the American public and fostered widespre…

Between 1933 and 1944, Americans huddled around their radios to listen to the words of Franklin Delano Roosevelt, the 32nd President of the United States. Covering topics ranging from the 1936 recess…

Neuroendocrine tumours (commonly referred to as NETs) is the topic for this week's episode of Oncology for the Inquisitive Mind. Michael and Josh thought it could be easily covered in a single episod…

Previously, on Oncology for the Inquisitive Mind, Josh and Michael discussed the common systemic therapies available for early and advanced testicular cancer: single-dose carboplatin and bleomycin + …

On this, the tenth episode of OncoSnacks, Josh and Michael discuss the management of a common but no less important problem: superficial venous thrombosis and thrombophlebitis. While for the majority…

Edward Gibbon, an English historian and politician, once quipped, "History is indeed little more than the register of the crimes, follies, and misfortunes of mankind." This episode, which lacks histo…

In this episode, the Nautilus reaches its final destination, where Michael and Josh pursue a deeper understanding of ROS1, and KRAS mutated lung cancer. ROS1 reflected less than 3% of non-small cell …

In this episode, Michael and Josh step onto the oncological Nautilus, to begin their journey 20,000 Leagues Under Lung Cancer, to examine non-small cell lung cancer with mutations other than EGFR. Th…

There are cancers that grow slowly. There are cancers that do not grow at all. And then there are cancer's like today's subject, that are notorious not just for their ability to completely overcome a…

Chemotherapy extravasation can occur day or night, and one must always be vigilant. While many agents are irritants and may not pose significant risks, vesicants pose a different story. A tale of dan…

Cancer is thought of as a great killer, an indefatigable bogeyman that claims the lives of everyone it afflicts. However, advances in medicine mean that for more people than ever before, cancer is so…

DCIS (ductal carcinoma in situ) and LCIS (lobular carcinoma in situ) are challenging areas of breast cancer oncology. Michael and Josh return from their short hiatus to find their podcast has been ra…

Theodore Roosevelt is famously quoted saying: "It is hard to fail, but it is worse never to have tried to succeed." This is what ASCO, oncologists and cancer researchers are faced with daily. As our …

The epic journey of Josh and Michael across tumour streams at ASCO 2023 is approaching its end. It has been a whirlwind tour through groundbreaking science, hazard ratios and exciting glimpses into a…

Every epic journey has that moment when the end is in sight. The start of the last lap of the race, the final dramatic encounter with the main villain. On this episode of Oncology for the Inquisitive…

Cancer is facing a seismic shift as precision oncology is becoming a reality, and adoption is skyrocketing as new anti-cancer agents are released. It appears that the days of blunt-force chemotherapy…

ASCO 23 explored novel anti-cancer agents in the genitourinary space. The future of oncology is etching closer daily. In this episode, Michael and Josh dissect ertafitinib, an FGFR inhibitor used in …

ASCO 2023 has been an incredible journey, and the latest instalment of Michael and Josh's search for the latest and greatest oncological news is no exception. On this episode, our intrepid duo examin…

In this episode, Michael and Josh investigate Lung Oncology research presented at ASCO 23, specifically early lung cancer treatment. They discuss Perioperative Toripalimab, LAG3 inhibitor Relatlimab …

Ovarian, cervical and endometrial cancer need more treatment options. Platinum-based chemotherapy only works for so long. ASCO 23 delivers with the practice-changing MIRASOL study introducing Mirvetu…